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jor cause of death in patients with
type 2 diabetes. Unclear, however,
is the effect of intensive therapy in reduc-
ing the development of cardiovascular
complications. The UK Prospective Dia-
betes Study (UKPDS), involving patients
with newly diagnosed disease, showed a
nonsigniﬁcant trend in the reduction of
rates for myocardial infarction (MI) (1).
However, data 10 years after cessation of
the trial showed a 15% reduction in the
risk of MI for those in the original inten-
sive therapy group (2). This beneﬁt from
early intensive therapy persisted despite
the fact that the within-trial differences
for A1C between the intensive and con-
ventionaltherapygroupswerelostwithin
1 year of completion of the trial. The sus-
tained beneﬁt from early aggressive treat-
ment is referred to as the legacy effect or
metabolic memory.
The question of more intensive
therapyandreductionincardiovascular
complications was addressed for people
with type 2 diabetes of long duration in
three other studies (i.e., the Action to
ControlCardiovascularRiskinDiabetes
[ACCORD] [3], the Action in Diabetes and
VascularDisease:PreteraxandDiamicron
Modiﬁed Release Controlled Evaluation
[ADVANCE] [4], the Veterans Affairs Di-
abetes Trial [VADT] [5]). Although the
three studies utilized different patient co-
horts, with varying durations of diabetes
(ACCORD, 10 years; VADT, 11.5 years;
and ADVANCE, 8 years) and had differ-
ent treatment regimens, the results of
these trials indicated that intensive glu-
cose control did not reduce CVD events.
In fact, the ACCORD trial was terminated
early because an increased rate of mortal-
ity was found to be associated with inten-
sive control of hyperglycemia (6). A
higherrateofmortalityforthoseoninten-
sivetreatmentwasnot,however,foundin
ADVANCE and VADT. Recent articles
from the ACCORD trial, by Pop-Busui et
al. (7) and Calles Escandon et al. (8), ex-
amined whether the effects of cardiovas-
cular autonomic neuropathy (CAN) or
self-reported history of neuropathy at
baseline could have been a contributor to
the higher mortality risk in the intensive
glycemic arm.
Physiological activities of the cardio-
vascular system are under the control of
the autonomic nervous system. Damage
to the autonomic nerves that innervate
the heart and blood vessels results in dys-
functioninheartratecontrolandvascular
dynamics (i.e., CAN) (9). Autonomic im-
balance between the sympathetic and
parasympatheticnervoussystems’regula-
tion of cardiovascular function contrib-
utes to metabolic abnormalities (10) and
signiﬁcantmorbidityandmortalityforin-
dividuals with diabetes (11–13). Clinical
manifestations of cardiovascular auto-
nomic dysfunction (e.g., exercise intoler-
ance, intraoperative cardiovascular
liability, orthostatic tachycardia and bra-
dycardia syndromes, silent myocardial
ischemia) can result in life-threatening
outcomes (11,12). In fact, the ultimate
outcome of increased risk of mortality is
clearlyassociatedwiththepresenceofau-
tonomic dysfunction (12). Results from
theACCORDtrialagainconﬁrmedtheas-
sociation of CAN and mortality. These in-
vestigators showed that the individuals in
this trial with baseline CAN were 1.55–
2.14 times as likely to die as individuals
without CAN (7). Furthermore, CAN in
the presence of peripheral neuropathy
was the highest predictor of CVD mortal-
ity (i.e., hazard ratio [HR] 2.95, P 
0.008). Indeed, combining indexes of au-
tonomic dysfunction have been shown to
be associated with the risk of mortality
(12–14).
In the ACCORD trial, assessment of
CAN included heart rate (reﬂecting over-
allautonomicfunctionandcardiorespira-
tory ﬁtness), a measure of heart rate
variability (i.e., time domain marker of
overall autonomic function–SD of nor-
mally conducted R-R intervals [SDNN]),
and QT index (reﬂecting sympathetic
function) computed from 10-s resting
electrocardiograms (7). The investigators
did not ﬁnd that the presence of CAN ap-
peared to contribute to the increased
mortality observed in the intensive versus
standard glycemic therapy group. Unfor-
tunately,thereisnoconsensusonthebest
measures for assessing CAN, thus it is
possible that there was an underestima-
tion of the impact of autonomic dysfunc-
tion based on methodological issues. It
shouldbenotedthatanonstatisticallysig-
niﬁcant (P  0.07) trend toward an in-
creased incidence of CAN (based on the
development of autonomic symptoms) in
patients on intensive versus standard
therapy was shown in the VADT (5). Re-
sults from the Detection of Ischemia in
Asymptomatic Diabetics (DIAD) study
showed that the presence of cardiac auto-
nomic dysfunction (deﬁned via change in
heart rate from lying to standing, a mea-
sure reﬂecting parasympathetic dysfunc-
tion) was among the highest HR (4.33)
associated with the primary events (i.e.,
cardiac death or nonfatal MI) (15). Just as
the number and type of assessment mo-
dalities used to identify the presence of
CAN affects prevalence rates and the as-
sociation with mortality (12), the meth-
ods in the ACCORD trial used to assess
CAN may have affected the ability to de-
termine an association with intensive glu-
cose therapy and mortality.
Itiswellknownthatpriorhypoglyce-
micepisodesattenuatetheresponseofthe
autonomic nervous system to subsequent
hypoglycemia (16). Recently, it has been
suggested that prior hypoglycemia could
attenuate the autonomic response to spe-
ciﬁc cardiovascular stresses (17). These
ﬁndings have signiﬁcant clinical implica-
tions given that antecedent hypoglycemia
attenuatescardiovascularautonomiccon-
trol and thus could impact the use of rig-
orous glycemic control in individuals
with diabetes. Nonetheless, antecedent
hypoglycemia associated with CAN did
not appear to explain the increase in
mortality associated with rigorous con-
trol reported in the ACCORD study (7).
It should be noted, however, that in
post hoc comparisons between the in-
tensive and standard glycemic arms in
the ACCORD trial, a differential effect on
mortality was found for those that self
reported history of neuropathy (8). The
disparity between different forms of neu-
ropathy as a predictor of outcomes has
been shown by others. In the ACCORD
study (8), the Michigan Neuropathy
Screening Instrument (MNSI) detected
peripheral neuropathy in 4,357 patients,
whereas only 2,737 reported a history of
neuropathy. Of those who reported a his-
tory of neuropathy, 61% had a MNSI
score that indicated neuropathy. In the
DIAD study, a relationship with CVD was
found with numbness and absent sensa-
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vibration, or absent reﬂexes (15). Painful
neuropathy, however, is associated with
abnormal autonomic function, which
may be a consequence of the pain (18).
Gaede et al. (19) showed that multifacto-
rial treatment improved CAN without an
impact on peripheral neuropathy, mea-
sured with a biothesiometer. Johnson et
al. (20) found that almost three-fourths
(119 of 148) of diabetic individuals with
long-standing diabetes and peripheral
neuropathy,whowerepotentiallyeligible
for an intervention trial, had baseline
functional cardiac abnormalities but no




ciated (15). The reason for the disparity
between the association of intensive ther-
apy,mortality,anddifferentformsofneu-
ropathy is unclear. Further study on the
difference between somatic and auto-
nomic neuropathy as predictors of, or
contributors to, CVD is warranted.
Mortality occurred in both treatment
arms of the ACCORD trial. Excessive risk
with intensive versus standard strategy
occurred when patients in the intensive
groupfailedtoreduceA1Cwithintheﬁrst
year (8). It was the individuals who failed
toachievegoaleasilywhosufferedevents.
As suggested by Calles-Escandon et al.
(8), individuals with poorer glycemic
control at baseline may be those with dis-
ease that is more difﬁcult to manage or
perhaps those who were less adherent to
treatment. It may well be that the pres-
ence of polyneuropathy or CAN should
caution against aggressive and rapid
blood glucose lowering if it cannot be
achieved easily. Results generated from
the U.K. General Practice Research Data-
base showed a U-shaped association of
glycemic control and events, with the
lowest HR at an A1C of 7.5% (21). This
mean glycated hemoglobin value of
7.5% was associated with lowest all-
cause mortality and lowest progression to
large-vessel disease events. Low and high
meanA1Cvalueswereassociatedwithin-
creasedmortalityandcardiacevents(21).
Although these were observational analy-
ses, knowledge that individuals have so-
matic or autonomic dysfunction may
warrant relaxation of intensity and haste
to achieve control.
Given that intensive glucose therapy
hasbeenshowntobeaffectiveinreducing
risk for any diabetes-related end point for
patients with newly diagnosed type 2 di-
abetes (2), attention by health care pro-
viders should be made for the early
identiﬁcation of individuals with diabetes
and treatment according to the current
guidelines early on in the disease process.
Post hoc subgroup analysis of the VADT
showed that intensive glycemic control
had a greater CVD beneﬁt for those indi-
viduals with duration of diabetes 15
years compared with those with longer
duration (5). The window of opportunity
is early.
The lack of effect of intensive glyce-
mic control on the reduction of CVD
events in individuals with type 2 diabetes
of longer duration heightens the impor-
tance of other risk factors in the disease
process and emphasizes the need for a
multifactorial approach of treatment. In
the Steno-2 Study (19), where people
with type 2 diabetes received intensive
multifactorial treatment (e.g., targeting
hyperglycemia, hypertension, dyslipide-
mia, and microalbuminuria, along with
secondary prevention of CVD with aspi-
rin),theapproachreducedtheriskofcar-
diovascular events by 53% and also
reduced autonomic dysfunction by 63%.
In terms of the multifactorial approach,
the glucose-lowering agents appeared to
have the least effect when compared with
antihypertensive treatment, lipid-lowering
agents, aspirin, and vitamin-mineral sup-
plements. It should also be noted that the
ﬁndings of the multifactorial approach
were seen after 7.8 years of follow-up.
Given that this multifactorial approach
took 8 years for the difference to
emerge, and the overall mortality rate at
3.5 years in the ACCORD trial was lower
than seen in earlier studies of similar pa-
tients(22,23),itispossiblethattheinten-
sive arm was terminated prematurely
with the beneﬁt potentially emerging
later.
The lesson to be learned from the
ACCORD study is that somatic and auto-
nomicdysfunctionaresigniﬁcantriskfac-
tors for CVD with HRs that transcend
traditional risk factors. It should be em-
phasized that patients with neuropathy
represent a high-risk group in which ag-
gressive diabetes treatment strategies
have to be weighed against the risk. Iden-
tiﬁcation of the presence of neuropathy is
pivotal. In addition, there is something
more that should be learned from the use
of markers of somatic/autonomic nerve
function in predicting outcomes. These
observations should guide investigators
intowhatcreatesthisdistinctionandhow
thisshouldimpactfurthertrialsonreduc-
ing cardiovascular risk. Whether it will
sufﬁce to use simple examination of heart
rate variability and heart rate using elec-
trocardiogram strips and a history of pe-
ripheral neuropathy to predict major
adverse cardiovascular events remains to
be studied.
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